IL6 and Alzheimer disease: Our 13-analyte panel calculations indicate that future senolyic trials could expect to achieve an effect size of 0.815 with an assumed attenuation of 0.6 between baseline and post-treatment SASP factor composite scores using as few as 25 participants/arm in an AD relevant trial population compared to 181 participants/arm if only one SASP factor (e.g. IL-6) were considered (Supplementary Table 2).